Recombinant Human EGF (Epidermal Growth Factor) is a peptide that binds to the membrane receptor called EGF receptor in humans to promote cell proliferation and cell differentiation. EGF acts by initiating number of cell signaling cascade pathways such as activating genes for cell proliferation, cell differentiation, protein synthesis, and improving efficiency of DNA topoisomerase. Traditionally, EGF was isolated from animal urine but with recent advances in biotechnology, the production and extraction of recombinant EGF have become possible in a lab setting. Recombinant EGF can be produced using various biological systems such as Escherichia coli, tobacco, rice, yeast, and others. EGF can be used for several applications in the field of medicine, research, cell culture, cosmetology, and others. EGF exhibits medically important properties such as initiation of growth and division in cells that can be exploited for clinical application of wound healing as well as for the treatment of ulcers. For instance, according to an article published by the American Institute of Physics in June 2020, high levels of recombinant human EGF (rhEGF) were obtained by co-expression of human EGF (hEGF) in Escherichia coli with Bacillus cereus phospholipase C. This rhEGF can then be used for the treatment of diabetic foot ulcers along with other wound treatments.

Market Dynamics

Market players are conducting clinical trials for analyzing the potential uses of human EGF in healthcare sector, this could contribute to the growth of the market over the forecast period. For instance, a clinical trial study was initiated in July 2017 by Hallym University Kangnam Sacred Heart Hospital, Korea, for determining the effectiveness of recombinant human EGF ointment in healing lesions caused by laser treatment for solar lentigines. The study was completed in December 2018 and the results were published by PubMed in February 2021. Results showed that the use of recombinant human EGF ointment was safe and efficient for healing lesions.

Market players are involved in acquisitions of other companies in order to enhance distribution. For instance, in 2018, FUJIFILM, a Japanese multinational conglomerate, acquired Irvine Scientific Sales Company, Inc., a cell media specialist, to expand its range of cell culture media products including recombinant human EGF. This is expected to drive the growth of the recombinant human EGF market.

Key features of the study

• This report provides an in-depth analysis of global recombinant human EGF market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global recombinant human EGF market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global recombinant human EGF market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the recombinant human EGF market

Market Segmentation

• By Product Type (Revenue, USD Bn, 2021-2033)
  • Heparin Binding-EGF
  • Transforming Growth Factor-α
  • Epigen
  • Neuregulins
  • Amphiregulin
  • Betacellulin
  • Others
• By Purity (Revenue, USD Bn, 2021-2033)
  • 98% SDS-PAGE
  • 95%-98% SDS-PAGE
  • <95% SDS-PAGE
• By Carrier Type (Revenue, USD Bn, 2021-2033)
  • Carrier Protein
  • Carrier Free
• By Formulation (Revenue, USD Bn, 2021-2033)
  • Lyophilized Powder
  • Liquid
  • Others
• By Application (Revenue, USD Bn, 2021-2033)
  • Wound Healing
  • Gastrointestinal Ulceration
  • Brain Tumor Therapy
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Thermo Fisher Scientific
  • FUJIFILM Irvine Scientific, Inc.
  • ScienCell Research Laboratories
  • R&D Systems
  • Abcam PLC
  • Cell Sciences, Inc.
  • Eurofins DiscoverX
  • PeproTech, Inc.
  • RayBiotech, Inc.
  • Prospec-Tany TechnoGene Ltd.
  • Miltenyi Biotec
  • Tonbo Biosciences
  • BioLegend, Inc.
  • EnQuire BioReagents
  • STEMCELL Technologies Inc.
  • Cell Guidance Systems Ltd.
  • Creative BioMart
  • Sino Biological Inc.
  • BioVision, Inc.